Michaela Schlederer
Overview
Explore the profile of Michaela Schlederer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noorizadeh R, Sax B, Javaheri T, Radic-Sarikas B, Fock V, Suresh V, et al.
Cell Rep
. 2025 Mar;
44(3):115381.
PMID: 40080499
Ewing sarcoma (EwS) is an aggressive cancer of adolescents in need of effective treatment. Insulin-like growth factor (IGF)-1 is an autocrine growth factor for EwS, but only 10% of patients...
2.
Sternberg C, Raigel M, Limberger T, Trachtova K, Schlederer M, Lindner D, et al.
Mol Cancer
. 2024 Nov;
23(1):245.
PMID: 39482716
Background: Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles IL6ST-mediated signaling pathways play in the development and progression of...
3.
Ning J, Spielvogel C, Haberl D, Trachtova K, Stoiber S, Rasul S, et al.
Theranostics
. 2024 Sep;
14(12):4570-4581.
PMID: 39239512
: This study aims to assess whole-mount Gleason grading (GG) in prostate cancer (PCa) accurately using a multiomics machine learning (ML) model and to compare its performance with biopsy-proven GG...
4.
Gruber E, Oberhuber G, Schlederer M, Birner P, Jomrich G, Schoppmann S, et al.
Sci Rep
. 2024 Jul;
14(1):15988.
PMID: 38987552
AF1q associates with tumor progression and metastases upon WNT signaling. The downstream WNT target CD44 has demonstrated prognostic significance in gastric cancer (GC). This study evaluates the impact of AF1q...
5.
Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, et al.
Mol Cancer
. 2024 May;
23(1):114.
PMID: 38811984
Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic...
6.
Pucci P, Lee L, Han M, Matthews J, Jahangiri L, Schlederer M, et al.
Nat Commun
. 2024 Apr;
15(1):3422.
PMID: 38653965
Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitating...
7.
Minas T, Han J, Javaheri T, Hong S, Schlederer M, Saygideger-Kont Y, et al.
Oncotarget
. 2024 Feb;
15:143.
PMID: 38386842
No abstract available.
8.
Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S, et al.
Mol Cancer
. 2023 Aug;
22(1):133.
PMID: 37573301
Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood....
9.
Sorger H, Dey S, Vieyra-Garcia P, Poloske D, Teufelberger A, de Araujo E, et al.
EMBO Mol Med
. 2022 Nov;
14(12):e15200.
PMID: 36341492
Leukemic cutaneous T-cell lymphomas (L-CTCL) are lymphoproliferative disorders of skin-homing mature T-cells causing severe symptoms and high mortality through chronic inflammation, tissue destruction, and serious infections. Despite numerous genomic sequencing...
10.
Kiss A, Wu P, Schlederer M, Pilz P, Szabo P, Li J, et al.
Basic Res Cardiol
. 2022 Aug;
117(1):42.
PMID: 36008727
Sympathetic nerve denervation after myocardial infarction (MI) predicts risk of sudden cardiac death. Therefore, therapeutic approaches limit infarct size, improving adverse remodeling and restores sympathetic innervation have a great clinical...